» Articles » PMID: 27568671

Clinical and Histopathological Profile of BRAF V600E Mutation in Conventional Papillary Thyroid Carcinoma in a Filipino Population

Overview
Journal Malays J Pathol
Specialty Pathology
Date 2016 Aug 30
PMID 27568671
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: BRAF V600E is a possible biomarker for risk stratification and prognostication in papillary thyroid carcinoma. Studies on its association with aggressive clinicopathological features among East Asian populations are limited. This study examines the clinical and histopathological features of this mutation in Filipinos with conventional papillary thyroid carcinoma.

Methods: Formalin-fixed, paraffin embedded thyroid tissue blocks of papillary carcinoma for the study period January 2010 to December 2012 were retrieved. Slides were reviewed and described according to tumour size, variant type, sclerosis, multifocality, subcapsular location, extra-thyroidal extension, nodal metastasis, and nodal extracapsular spread. Medical records were reviewed for patient demographics and characteristics. Mutation status was determined using realtime polymerase chain reaction and sequencing.

Results: Sixty-five patients were included in this study. BRAF V600E mutation prevalence was 38.46%. The mutation positive group was predominantly female, young (mean age 36 years), with tumour size less than 4 cm, and late-stage disease. Extra-thyroidal extension (60%), significant sclerosis (96%), and subcapsular tumour location (72%) were the most frequent findings. Eighty-three percent of patients with nodal metastasis had extracapsular spread.

Conclusions: Compared to some Asian populations, this study of Filipino patients shows a lower prevalence of BRAF V600E mutation. The clinical and histopathological features of mutation positive patients raise important issues regarding extent of surgical excision and appropriate management of neck metastasis for this group.

Citing Articles

Association of BRAF V600E Mutation with Tumor Recurrence in a Small Sample of Filipino Patients with Papillary Thyroid Cancer in a Single Center.

Chiu H, Macalalad-Josue A, Corpuz D, Paragas S, Pintor O, Hernandez-Diwa M Acta Med Philipp. 2024; 57(6):40-45.

PMID: 39483692 PMC: 11522634. DOI: 10.47895/amp.vi0.4972.


Profile of V600E, K601E, , and Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital.

Harahap A, Subekti I, Panigoro S, Asmarinah , Lisnawati , Werdhani R Appl Clin Genet. 2023; 16:99-110.

PMID: 37255533 PMC: 10226481. DOI: 10.2147/TACG.S412364.


Incidence, Recurrence and Mortality Among Filipinos With Differentiated Thyroid Cancer: A Systematic Review.

San Juan M, Paz-Pacheco E J ASEAN Fed Endocr Soc. 2023; 38(1):100-107.

PMID: 37252408 PMC: 10213166. DOI: 10.15605/jafes.038.01.14.


Younger Than 55 Years Old and V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm.

Lai Y, Gu Y, Yu M, Deng J Int J Gen Med. 2023; 16:1403-1414.

PMID: 37155469 PMC: 10122992. DOI: 10.2147/IJGM.S408588.


Characterization of mortality and high-risk characteristics of thyroid cancer in Filipinos using the California Cancer Registry.

Hsu R, Tsai K, Chennapan K, Wojcik K, Lee A, Nieva J Front Public Health. 2023; 10:1104607.

PMID: 36743179 PMC: 9893642. DOI: 10.3389/fpubh.2022.1104607.